Related Experiment Video
Updated: Aug 16, 2026
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
Selective cytotoxicity of azatyrosinamides against ras-transformed NIH 3T3 cells
1Graduate Institute of Natural Products, Chang Gung University College of Medicine, 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan 333, Taiwan. hpw@mail.cgu.edu.tw
Abstract:
This study aims to develop novel azatyrosinamide compounds structurally modified from ras-specific antioncogenic azatyrosine. Analogues 4-15 were prepared and their inhibition on the growth of wild-type and ras-transformed NIH 3T3 cell lines was compared. Compound 12 was found to be the most active with IC50 16.5+/-2.2 microM which is 458-fold more potent than that of azatyrosine. The selective toxicity, defined as IC(50 wild-type)/IC(50 ras-transformed) for this compound was 138.5.
Insights
Researchers developed new azatyrosinamide compounds to fight cancer. Compound 12 showed significant potency against ras-transformed cells, offering a promising new anti-cancer agent.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Azatyrosine is a known antioncogenic agent targeting ras.
- Ras proteins are frequently mutated in various cancers, driving tumor growth.
- Development of novel inhibitors targeting ras-transformed cells is crucial.
Purpose of the Study:
- To synthesize novel azatyrosinamide analogues.
- To evaluate the inhibitory effects of these analogues on wild-type and ras-transformed NIH 3T3 cell lines.
- To identify potent and selective anti-cancer compounds.
Main Methods:
- Chemical synthesis of azatyrosinamide analogues (4-15).
- Cell-based assays to determine IC50 values for wild-type and ras-transformed NIH 3T3 cells.
- Calculation of selective toxicity based on IC50 ratios.
Main Results:
- Compound 12 demonstrated the highest activity against ras-transformed cells.
- Compound 12 exhibited an IC50 of 16.5+/-2.2 microM.
- This compound was 458-fold more potent than azatyrosine, with a selective toxicity of 138.5.
Conclusions:
- Novel azatyrosinamide analogues were successfully synthesized.
- Compound 12 represents a highly potent and selective inhibitor of ras-transformed cell growth.
- This compound holds potential as a therapeutic agent for ras-driven cancers.
